Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Summary

A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with chemotherapy as a second-line treatment in patients with advanced CRC

Timeline

Start

2021-03

Primary completion

2021-03

Completion

2023-12

Publications

• Su L, Lin P, Yin Y, Ye Z, Zhuo C, Wei S, Yu S, Li J, Hong Y, Zheng L, Zhao S, Chen Y, Li H, Lin R. Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. Ann Med. 2026 Dec;58(1):2698360. doi: 10.1080/07853890.2026.2698360. Epub 2026 Jul 9.

Drugs

Indications